URGN: ZUSDURI grew 35% QoQ as profitability is targeted for Q4 2026

What happened

Urogen Pharma reported ZUSDURI revenue of $68M, up 35% quarter over quarter, and total revenue of $89M. Management expects the company to reach profitability and generate positive cash flow in the fourth quarter of 2026. JELMYTO faces clinical-trial headwinds, while UGN-103 is advancing toward a 2027 FDA decision.

Confirmed

Global impact / market context

Higher ZUSDURI sales could support revenue growth, but the stated profitability and cash-flow goals remain expectations, not reported results. If achieved, positive cash flow could reduce the need to raise funds or borrow money; clinical-trial setbacks could instead raise costs or delay revenue.

Analyst inference

The update combines strong quarter-over-quarter growth in one product with uncertainty around another product’s trials and a future FDA decision. Investors may weigh whether ZUSDURI sales can sustain growth and cover costs before management’s fourth-quarter 2026 profitability target.

Analyst inference

What to watch

1. Track whether ZUSDURI revenue continues to grow and whether total revenue rises, since those reported figures indicate how much sales contribute toward covering company costs. Analyst inference
2. Watch for further information on JELMYTO’s clinical-trial headwinds; trial delays or setbacks could increase development costs or postpone potential revenue. Analyst inference
3. Follow UGN-103’s progress toward the 2027 FDA decision and management’s updates on reaching profitability and positive cash flow in Q4 2026. Analyst inference

Evidence

• Original source link unavailable